CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
44 hedge funds and large institutions have $20.7M invested in CASI Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
76% more capital invested
Capital invested by funds: $11.8M → $20.7M (+$8.95M)
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
16% more funds holding
Funds holding: 38 → 44 (+6)
0.16% more ownership
Funds ownership: 0.55% → 0.71% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.45M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
| 3 |
WSC
Wellington Shields & Co
New York
|
+$672K |
| 4 |
Goldman Sachs
New York
|
+$594K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$406K |
| 2 |
PA
Perceptive Advisors
New York
|
-$149K |
| 3 |
Barclays
London,
United Kingdom
|
-$76.6K |
| 4 |
RE
RBC Europe
London,
United Kingdom
|
-$65K |
| 5 |
AGM
Alpine Global Management
New York
|
-$58.9K |
CASI Hedge Fund Activity: Q1 2018 in Review
44 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2018, worth a combined $20.7M — up 76% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CASI positions and 3 closed out — a net gain of 6 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.45M. The largest seller was Renaissance Technologies, cutting an estimated $406K.
- 44 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2018, up from 38 in Q4 2017.
- Funds reported $20.7M of CASI Pharmaceuticals stock for Q1 2018, up 76% quarter-over-quarter.
- 9 funds opened new CASI Pharmaceuticals positions in Q1 2018 and 3 closed out, a net change of +6 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2018 was Millennium Management, an estimated $1.45M added.
- The largest CASI Pharmaceuticals seller in Q1 2018 was Renaissance Technologies, an estimated $406K sold.
Based on aggregated 13F filings for Q1 2018.